Evidence map›Paper›PMID 41585438›Full record

ArticleMaterials today. Bio2026

Biomimetic cancer cell membrane-coated liposomal nanocarriers loaded with silibinin suppress gastric cancer progression via SNHG1/miR-383-5p/HSP90AA1 axis-mediated PI3K/AKT pathway inhibition.

Jun Yao, Qiang Sun, Xin Zhang, Dejun Yang, Han Wu, Zunqi Hu, Qing You, Ziran Wei, Weijun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun YaoDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Qiang SunDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Xin ZhangDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Dejun YangDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Han WuDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Zunqi HuDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Qing YouDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Ziran WeiDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.
Weijun WangDepartment of Gastrointestinal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, 200003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) remains a major global health problem and demands more effective therapeutic approaches. In this study, we developed a novel biomimetic nanovesicle system-cancer cell membrane-coated liposomal nanocarriers loaded with silibinin (CLip@Sil)-designed for targeted therapy against GC. By integrating network pharmacology with transcriptomic profiling, we identified 13 key target genes, significantly enriched in the PI3K/AKT and IL-17 signaling pathways, with HSP90AA1 emerging as a central regulatory node. Further mechanistic investigation revealed that silibinin exerts its anticancer effect by modulating the SNHG1/miR-383-5p/HSP90AA1 competing endogenous RNA (ceRNA) axis, thereby suppressing the PI3K/AKT pathway. The engineered CLip@Sil system demonstrated enhanced tumor-targeting capacity via its biomimetic cancer-membrane coating, enabling selective drug delivery and accumulation in tumor tissues. In vitro studies confirmed that CLip@Sil inhibited GC cell proliferation, migration, and invasion, while promoting apoptosis. In vivo, CLip@Sil significantly suppressed primary tumor growth and lung metastasis, extended overall survival, and exhibited minimal systemic toxicity. These findings highlight the value of combining competing endogenous RNA regulatory networks with nanomaterial based targeted delivery systems for GC therapy. The CLip@Sil platform offers a promising direction for the future development of precise and biomimetic nanotherapeutics in oncology.

Indexed as

Gastric cancerHeat shock protein 90 alpha family class member 1Network pharmacologyPhosphatidylinositol 3-kinase/Protein kinase B signaling pathwaySilibinin

Identifiers

PMID41585438
PMCPMC12830297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.